News summaryYahoo Finance / BenzingaNov 9, 2026, 01:06 PM
Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success - Yahoo Finance
Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success - Yahoo Finance(摘要待生成)